
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is well positioned for continued growth because management still expects 2026 high-single-digit top-line expansion even after a downward revision to Baqsimi, signaling resilience in the broader portfolio. The company also expects Baqsimi margins to improve by discontinuing a small amount of international sales starting in 2H26, while peak sales expectations of $250MM-$275MM remain unchanged, supporting profitability and visibility. In addition, the recent launch of ipratropium bromide HFA has not faced additional competition and could become a $30MM-$40MM sales opportunity, reinforcing a constructive outlook.
Bears say
Amphastar Pharma is facing a weak fundamental setup because Baqsimi, its flagship product, is under sustained pricing pressure from higher rebates, 340B pharmacy discounts, and an unfavorable channel mix, with 1Q26 sales falling to $32.4M from $38.4M in 1Q25 and 2Q26 sales slipping to $45.5M from $46.7M in 2Q25 despite prescription growth. Competitive erosion is also weighing on the base business, as injectable glucagon sales dropped 56% in 1Q26 after Viatris’ generic entered in December 2024, while glucagon and epinephrine together still represented more than 15% of 1Q26 revenue. With 1Q26 non-GAAP EPS of $0.42 versus $0.71 expected and limited visibility into pipeline catalysts until 2027, the company faces margin pressure, slower growth, and weak near-term earnings momentum.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares